Literature DB >> 9624611

Epstein-Barr virus expression within keratinizing nasopharyngeal carcinoma.

J X Zhang1, H L Chen, Y S Zong, K H Chan, J Nicholls, J M Middeldorp, J S Sham, B E Griffin, M H Ng.   

Abstract

Three stages of maturation can be seen in keratinizing nasopharyngeal carcinomas. These stages are similar morphologically to basal cells, intermediate and superficial squamous cells seen in normal squamous epithelium. Taking advantage of such a diverse tumour cell population, 10 keratinizing nasopharyngeal carcinoma (NPC) were examined by in situ hybridization for the presence of latent Epstein-Barr Virus (EBV) using EBV encoded RNAs (EBERs) and by immunohistology for the presence of EBV early antigen-diffuse (EA-D) and the 350/220 kd membrane glycoprotein of the EBV. The basal cell-like tumour cells are mainly infected latently with the virus; viral replication was found in isolated intermediate squamous cells, whilst superficial squamous cells are largely depleted of all the viral markers. We used a control series of nonkeratinizing nasopharyngeal carcinomas composed of undifferentiated and poorly differentiated tumour cells and EBV latency was present in these tumours. Viral replication was detected by RT-PCR, in the undifferentiated tumours but viral replication was not seen by immunohistology. The possible relationship between EBV life cycle in these tumours and tumour cell differentiation is discussed in the light of these findings.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624611     DOI: 10.1002/(sici)1096-9071(199807)55:3<227::aid-jmv8>3.0.co;2-3

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  16 in total

1.  The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity.

Authors:  H Chen; J M Lee; Y Wang; D P Huang; R F Ambinder; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia.

Authors:  Servi J C Stevens; Sandra A W M Verkuijlen; Bambang Hariwiyanto; Jajah Fachiroh; Dewi K Paramita; I Bing Tan; Sophia M Haryana; Jaap M Middeldorp
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

3.  The nuclear and adherent junction complex component protein ubinuclein negatively regulates the productive cycle of Epstein-Barr virus in epithelial cells.

Authors:  Henri Gruffat; Julien Lupo; Patrice Morand; Véronique Boyer; Evelyne Manet
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

4.  Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.

Authors:  J Fachiroh; D K Paramita; B Hariwiyanto; A Harijadi; H L Dahlia; S R Indrasari; H Kusumo; Y S Zeng; T Schouten; S Mubarika; J M Middeldorp
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

5.  Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity.

Authors:  Rosamaria Tedeschi; Elisa Pin; Debora Martorelli; Ettore Bidoli; Alessia Marus; Chiara Pratesi; Maria Teresa Bortolin; Stefania Zanussi; Emanuela Vaccher; Riccardo Dolcetti; Paolo De Paoli
Journal:  Clin Vaccine Immunol       Date:  2007-02-28

6.  Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen.

Authors:  S J Stevens; I Pronk; J M Middeldorp
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

7.  Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification.

Authors:  Claire Shannon-Lowe; Emily Adland; Andrew I Bell; Henri-Jacques Delecluse; Alan B Rickinson; Martin Rowe
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

8.  Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria.

Authors:  Hans Lassmann; Gerald Niedobitek; Francesca Aloisi; Jaap M Middeldorp
Journal:  Brain       Date:  2011-08-16       Impact factor: 13.501

9.  EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas.

Authors:  Abdelmajid Khabir; Hela Karray; Sandrine Rodriguez; Mathieu Rosé; Jamel Daoud; Mounir Frikha; Tahia Boudawara; Jaap Middeldorp; Rachid Jlidi; Pierre Busson
Journal:  Virol J       Date:  2005-04-20       Impact factor: 4.099

10.  Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.

Authors:  Nathan P Croft; Claire Shannon-Lowe; Andrew I Bell; Daniëlle Horst; Elisabeth Kremmer; Maaike E Ressing; Emmanuel J H J Wiertz; Jaap M Middeldorp; Martin Rowe; Alan B Rickinson; Andrew D Hislop
Journal:  PLoS Pathog       Date:  2009-06-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.